These data suggest that ABCB1 and survivin may act in promoting resistance in CML patients and, thus, reinforce the hypothesis that ABCB1 is able to induce resistance independently of its activity function [145]. Here, BIRC5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.